Abstract
Cyclophosphamide (CyP) is the immunosuppressive agent of choice in ocular MMP. However, guidelines do not specify the regimen modality of CyP treatment. We introduce our practical management protocol for ocular MMP utilizing fixed-low dose intravenous pulses of CyP followed by IV rituximab, accompanied by two case studies in elderly patients who achieved complete and enduring remissions without adverse effects.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
